Amrutanjan Health Care Ltd.

510.65

11.1 (2.2%)growUp

AMRUTANJAN Share Price
As on April 2, 2026
SectorHealthcare
IndustryPharmaceuticals & Biotechnology
Basic IndustryPharmaceuticals
Market Cap1,472 Cr
P/E Ratio72.55
Dividend Yield0.38 %
Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock_ipo_icon.webpUnlock Stock of the Month

T&C*

Company Information


Market Insights
Open499
High515.95
NSE SymbolAMRUTANJAN
Close510.65
Low489.25
BSE Symbol590006
Previous Years High/Low
1 Year High790.95
3 Year High862.6
5 Year High1,024.55
1 Year Low486
3 Year Low486
5 Year Low486

Technicals


IndicatorsValueSignal
5-DMA506.48Bullish
10-DMA512.94Bearish
20-DMA531.98Bearish
50-DMA578.42Bearish
100-DMA625.43Bearish
200-DMA670.14Bearish

Historical Performance


1 Year
-20.9%
3 Years
-11.3%
5 Years
-11.3%
10 Years
142.3%

Shareholding Pattern


Values Analysis


Loading chart...

Profit & Loss

Below figures are in Rs. Crores


ParticularsMar-2016
Net Sales1,867
Total Expenditure1,560
Other Income57
Operating Profit365
Interest4
Depreciation33
Profit Before Tax327
Consolidated Net Profit206
Adjusted EPS7
Compounded Sales Growth
10 Years:0
5 Years:0
3 Years:0
TTM:0
Compounded Profit Growth
10 Years:0
5 Years:0
3 Years:0
TTM:0
Stock Price CAGR
10 Years:9.3
5 Years:-2.4
3 Years:-6
TTM:-23.3
Return on Equity
10 Years:1.8
5 Years:3.3
3 Years:4.3
last year:7

Quarterly Results

Below figures are in Rs. Crores


ParticularsSep-2024Dec-2024Mar-2025Jul-2025Sep-2025
Sales1,70,7541,35,9361,28,5521,22,1891,05,161
Expenses63,04256,55752,45745,45934,856
Operating Profit1,07,71279,37976,09676,73070,304
OPM %63%58%59%63%67%
Other Income33,91231,75927,33324,87918,947
Interest77,78058,58459,24862,13753,713
Depreciation2,3451,6811,3851,2771,221
Profit Before Tax61,49850,87342,79638,19534,318
Tax %25%25%26%29%35%
Net Profit46,14938,15131,85727,29622,446
EPS in Rs8369585042

Balance Sheet

Below figures are in Rs. Crores


ParticularsMar-2016
Share Capital29
Total Reserves1,058
Long-Term Borrowings---
Total Non-Current Liabilities37
Other Current Liabilities144
Short Term Borrowings25
Total Liabilities1,404
Capital Work in Progress7
Long Term Loans & Advances13
Currents Investments---
Short Term Loans and Advances121
Total Current Assets1,005
Total Assets1,404
Adjusted Book Value37
0%
Positive
(80 to 100)
Neutral
(60 to 79)
Negative
(0 to 59)
  • The stock has a high PE of 72.55, indicating expensive valuation or elevated growth expectations.
  • Over the last three years, the stock delivered a weak 3-year price CAGR of -6.0%, indicating poor shareholder returns.
  • The stock carries a low beta of 0.6, suggesting lower volatility than the broader market.
  • In the last financial year, the company reported an EBITDA of ₹365 million, reflecting positive operating performance.
  • In the previous financial year, the company generated revenue of ₹1867 million, suggesting a mid-sized operation.

Investment Calculator


Investment Amount:

Investment Amount: ₹ 1000000
Current Value: ₹ 766856.9
No. of Shares: 1502 (Approx)
Performance:-23.3%
P/L: ₹-233143.1
NIFTY Performance: -2.3%
1 day Top Gainers
SymbolChange%
LATENTVIEW312.1(20%)
OLAELEC28.34(10%)
TATACHEM651.9(7%)
CARBORUNIV854(6%)
BSOFT370.85(6%)
1 Day Top Losers
SymbolChange%
KARURVYSYA272.65(-7%)
UBL1485.1(-6%)
PGEL454.45(-6%)
CGCL166.33(-6%)
SRF2416.1(-5%)
AMBER6281.5(-5%)
GRSE2255.3(-4%)
ASTERDM658.1(-4%)

Top Performing Stocks from the same sector


Venus Remedies Ltd.

37.6%

896.6

1 Month Performance

Beta Drugs Ltd.

31.6%

1387.2

1 Month Performance

Shilpa Medicare Ltd.

20.2%

388.9

1 Month Performance

Strides Pharma Science Ltd.

15.3%

971.15

1 Month Performance

Jagsonpal Pharmaceuticals Ltd.

13.2%

186.22

1 Month Performance

Balaxi Pharmaceuticals Ltd.

11.9%

21.12

1 Month Performance

Aurobindo Pharma Ltd.

10.2%

1333.7

1 Month Performance

Bliss GVS Pharma Ltd.

9.5%

234.18

1 Month Performance

Get Your Portfolio Reviewed

Stock of the Month
Stock of the Month